<DOC>
	<DOCNO>NCT00433329</DOCNO>
	<brief_summary>An open label , non-comparative study design appropriate Phase 4 study design ass whether core therapy bosentan , either monotherapy addition sildenafil , enable patient pulmonary arterial hypertension ( PAH ) achieve 6-minute walk distance ( 6 MWD ) ≥380 meter 28 week therapy This design also appropriate pioneer utility cardiac MRI assess improved functional capacity PAH explore correlation parameter .</brief_summary>
	<brief_title>Combination Therapy Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Signed informed consent prior initiation studymandated procedure . 2 . Males females ≥ 12 year age ( female childbearing potential must surgically sterilize use reliable method contraception ) . 3 . Symptomatic patient follow type PAH belong World Health Organization ( WHO ) Pulmonary Hypertension Classification Group I : Idiopathic ( IPAH ) Familial ( FPAH ) Associated PAH ( APAH ) : Collagen vascular disease Drugs toxins 4 . Patients naïve treatment advance PAH therapy ( i.e. , endothelin receptor antagonist ( ERAs ) , phosphodiesterase5 ( PDE5 ) inhibitor prostacyclins ) right heart catheterization ( RHC ) show follow : Mean pulmonary arterial pressure ( mPAP ) ≥ 25 mm Hg Pulmonary capillary wedge pressure ( PCWP ) ≤ 15 mm Hg leave ventricular end diastolic pressure ( LVEDP ) ≤ 15 mm Hg PCWP accurately obtain Pulmonary vascular resistance ≥ 3 Wood unit 5 . 6MWT distance ≥ 150 meter &lt; 360 meter . 1 . Patients Pulmonary Hypertension ( PH ) belonging WHO Classification Group IIV . 2 . Patients PAH ( WHO PH Classification Group I ) list Inclusion Criteria . 3 . Pregnant and/or nursing . 4 . Women childbearing potential use reliable method contraception . 5 . Patients know human immunodeficiency virus ( HIV ) infection . 6 . Patients significant vasoreactivity right heart catheterization ( i.e. , fall mPAP &lt; 40 mm Hg decrease ≥ 10 mm Hg normal cardiac index ≥ 2.5 l/min.m^2 ) . 7 . Patients restrictive lung disease ( i.e. , total lung capacity ( TLC ) &lt; 60 % normal predict value ) . 8 . Patients obstructive lung disease ( i.e. , force expiratory volume/ force vital capacity ( FEV1/FVC ) &lt; 0.5 ) . 9 . Patients impaired leave ventricular function ( LVEF &lt; 50 % ) diastolic dysfunction . 10 . Patients portal hypertension , cirrhosis , moderate severe liver impairment ( ChildPugh Class B C ) , liver enzymes ( Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) ) &gt; 3.0 time upper limit normal range . 11 . Treatment glibenclamide ( glyburide ) calcineurin inhibitor ( cyclosporine A , tacrolimus ) sirolimus , everolimus 1 week prior Baseline ( Day 1 ) . 12 . Patients currently receive predict require treatment , course study , nitrate , protease inhibitor , alphablockers . 13 . Patients hemoglobin concentration &lt; 75 % low limit normal range &lt; 8.5 g/dL . 14 . Patients currently receive predict require treatment prostanoid course study . 15 . Patients systolic blood pressure &lt; 85 mm Hg . 16 . Patients body weight &lt; 40 kg . 17 . Patients receive investigational product within 90 day prior Baseline . 18 . Patients previously receive advanced therapy PAH ( e.g. , ERAs , PDE5 inhibitor prostacyclins ) . 19 . Patients hypersensitivity sildenafil excipients formulation . 20 . Patients contraindication sildenafil treatment ( i.e. , nitrate ) . 21 . Patients recent medical condition limit ability comply study requirement ( i.e. , stroke , myocardial infarction ) . 22 . Patients unstable PAH whose disease state would prohibit completion study procedure , opinion investigator . 23 . Patients unable complete MRI scan ( e.g. , claustrophobia ) . 24 . Patients permanent cardiac pacemaker , automatic internal cardioverter defibrillator ( AICD 's ) , neurostimulators , hear aide , implant metallic device contraindicate MRI study . 25 . Patients condition would interfere proper cardiac gating MRI , atrial fibrillation multiple premature ventricular contraction ( PVCs ) /premature atrial contraction ( PACs ) . 26 . Patients condition prevent compliance protocol ability adhere therapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>bosentan</keyword>
	<keyword>sildenafil</keyword>
	<keyword>combination therapy</keyword>
	<keyword>Compass 3</keyword>
</DOC>